Tango Therapeutics presented preclinical data on TNG‑456, a selective MTA‑cooperative PRMT5 inhibitor engineered to exploit methylthioadenosine (MTA) biology in tumors such as glioma and metastatic non‑small cell lung cancer. Data highlighted potent antitumor activity in brain‑relevant models and supported the rationale for advancing PRMT5 inhibitors optimized for CNS penetration. Preclinical profiling emphasized selectivity and a cooperative mechanism designed to widen the therapeutic window in tumors with PRMT5 dependencies. Researchers argued that TNG‑456’s design addresses prior limitations in PRMT5 programs and positions it for clinical development in brain‑metastatic and primary CNS malignancies. These results add momentum to epigenetic‑targeted oncology programs and point to PRMT5 as a tractable node for drugging transcriptional dependencies in difficult‑to‑treat tumors.